Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis
Authors:
- S. C. MastbergenSMS. C. Mastbergen
- A. C. MarijnissenAMA. C. Marijnissen
- M. E. VianenMVM. E. Vianen
- B. ZoerBZB. Zoer
- P. M. van RoermundPRP. M. van Roermund
- J. W. BijlsmaJBJ. W. Bijlsma
- F. P. LafeberFLF. P. Lafeber
Open Access
- 15 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (4) , 405-413
Abstract
Objective. In vitro studies showed a beneficial effect of celecoxib on proteoglycan turnover and content of osteoarthritic cartilage. In the present study we evaluated whether these favourable effects of celecoxib could also be demonstrated in vivo. Methods. In 24 Beagle dogs, osteoarthritis (OA) was induced in one knee according to the groove model. The animals were divided into three groups and received oral placebo or 100 or 200 mg celecoxib daily, starting directly after surgery. After 15 weeks joint tissue from all dogs was analysed. Results. Induction of OA resulted in macroscopic and histological damage of cartilage, changes in cartilage proteoglycan turnover, loss of cartilage matrix proteoglycans and slight synovial inflammation, all characteristic of early OA. Surprisingly, none of the parameters was significantly changed upon celecoxib treatment. Synovial fluid prostaglandin E2 levels were dose-dependently diminished by celecoxib, demonstrating that the celecoxib had reached the joint in sufficient amounts. Using an in vitro setup, canine cartilage under degenerative conditions was favourably influenced by celecoxib, demonstrating that canine cartilage is sensitive to celecoxib. Conclusion. The present study showed a chondroneutral effect of celecoxib on the characteristics of experimentally induced OA in vivo, in contrast to the observed beneficial effect in vitro. It could be that celecoxib had been beneficial to degenerated cartilage in vivo but that these effects were counteracted by increased loading of the affected joint and the associated progression of OA, occurring because of the well-known analgesic effects of celecoxib.Keywords
This publication has 42 references indexed in Scilit:
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Gastrointestinal side‐effects of traditional non‐steroidal anti‐inflammatory drugs and new formulationsAlimentary Pharmacology & Therapeutics, 2004
- Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?The American Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Selective cyclooxygenase-2 inhibitors for the treatment of arthritisClinical Therapeutics, 1999
- COX-2 inhibitorsThe Lancet, 1999
- In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilageJournal of Orthopaedic Research, 1993
- Effects of Nimesulide and Naproxen on the Degradation and Metalloprotease Synthesis of Human Osteoarthritic CartilageDrugs, 1993
- Proteoglycan depletion, rather than fibrillation, determines the effects of salicylate and indomethacin on osteoarthritic cartilageArthritis & Rheumatism, 1985